Caristo Diagnostics Limited, based in Oxford, United Kingdom, specializes in artificial intelligence-driven software for cardiovascular diagnostics. Founded in 2018, the company focuses on improving heart health assessments through its advanced imaging technology. By developing tools that analyze Cardiac Computed Tomography Angiography (CCTA), Caristo enables the measurement of Fat Attenuation Index (FAI) during routine heart check-ups. This innovative approach enhances the diagnostic accuracy of coronary angiograms, allowing healthcare professionals to identify inflammation in the coronary arteries and predict risks of heart attacks, strokes, and diabetes. Through its proprietary technology, Caristo Diagnostics aims to support medical professionals in making informed treatment decisions to better manage cardiovascular health.
Opsydia Limited specializes in innovative laser marking technology that enables the creation of invisible structures within transparent materials. Founded in 2017 and based in Begbroke, United Kingdom, the company’s technology allows for the permanent and inimitable marking of serial numbers, images, and cryptographic data without altering the surface or compromising the integrity of materials like diamonds, glass, and polymers. This capability positions Opsydia to significantly enhance security and authenticity in various industries, particularly in diamond trading where identity verification is crucial. By embedding marks that are not visible to the naked eye, Opsydia's solutions provide a unique advantage in safeguarding valuable assets and improving overall material quality.
Brill Power Ltd. is a clean-tech company based in Oxford, United Kingdom, specializing in energy storage solutions using lithium-ion battery cells. Founded in 2016, the company focuses on developing advanced battery management technology that enhances the performance and longevity of battery packs. Its innovative control concepts and software are designed to significantly improve the efficiency and cost-effectiveness of battery systems, catering to applications in stationary energy storage and electric vehicles. Brill Power aims to provide sustainable energy solutions that benefit communities and contribute to a greener society.
Oxford Quantum Circuits developing technology using the power of quantum to do things which have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies.
MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on developing antibody modulators for immune cell receptors aimed at treating autoimmune diseases. Founded in 2018, MiroBio leverages pioneering research from the University of Oxford to understand how immune cells communicate and are activated. This foundational knowledge allows the company to create innovative antibodies that stimulate specific immune cell signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural pathways, MiroBio's therapeutics aim to provide significant benefits to patients suffering from various autoimmune conditions, enabling clinicians to effectively manage overactive immune responses associated with these diseases.
BibliU is a digital educational service designed to enhance the learning experience for university students. It provides access to a vast library of textbooks and monographs, allowing students to search for relevant materials easily. The platform also facilitates interaction among students and professors, promoting collaborative learning and engagement. By streamlining access to educational content, BibliU aims to make the learning process more efficient and effective.
ORCA Computing Limited, founded in 2019 and based in Oxford, United Kingdom, specializes in the development of photonic quantum computers. The company is focused on creating a scalable and flexible quantum computing platform that utilizes quantum memories to enhance performance. By integrating proprietary memory technology with standard telecom components, ORCA Computing delivers a modular architecture that optimizes the storage, synchronization, and buffering of quantum operations. This innovative approach aims to unlock advanced applications across various industries, thereby accelerating innovation and transforming traditional computing methods.
MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that specializes in developing sustainable agricultural technologies. Founded in 2017 as a spin-out from the University of Oxford, the company focuses on discovering new herbicide chemistries with innovative modes of action derived from both natural and synthetic sources. By utilizing a proprietary in vivo plant-based genomic process, MoA Technology identifies specific target proteins linked to these new modes of action, thus providing farmers with a diverse range of effective weed control solutions. The company's approach aims to enhance food production while promoting sustainable crop systems.
Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designed to exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
OMass Technologies Ltd engages in drug discovery by applying mass spectrometry to the characterization of intact protein assemblies. The company offers biotherapeutics, membrane proteins, drug binding, and purifications guiding services. In addition, OMass Technologies Ltd offers structural mass spectrometry (MS) platforms, often referred to as native mass spectrometry, for characterizing complex protein assemblies. The company assists biotechnology and pharmaceutical companies in tackling drug targets and biotherapeutics. OMass Technologies Ltd was founded in 2016 and is based in Begbroke, United Kingdom.
Scenic Biotech B.V., founded in 2017 and based in Amsterdam, specializes in developing genomics and immunotherapy technologies aimed at addressing cancer and rare genetic diseases at their genetic roots. The company focuses on identifying disease-suppressing genes that serve as "off-switches" for GPCR signaling, enabling innovative therapeutic interventions. Scenic Biotech's approach involves unlocking genetic modifiers that can suppress or block the effects of disease-causing mutated genes. This technology allows for the rapid identification and validation of novel drug targets, facilitating the development of disease-modifying therapeutics that aim to improve the lives of patients suffering from severe conditions.
First Light Fusion Limited is a company focused on developing advanced implosion processes for electricity generation. Founded in July 2011 as a spin-out from the University of Oxford, the company initially operated under the name Oxyntix Ltd. until a rebranding in June 2014. The founders, Professor Yiannis Ventikos and Dr. Nicholas Hawker, have backgrounds in mechanical engineering and academia. Based in Begbroke, United Kingdom, First Light Fusion employs a team of engineers and physicists and maintains collaborations with several prestigious academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company's mission is to innovate in the field of energy generation through cutting-edge research and technology.
PQShield Ltd specializes in quantum-secure cryptographic solutions aimed at addressing emerging security challenges posed by quantum computing. Founded in 2018 and based in Oxford, UK, the company originated as a spinout from the Mathematical Institute at the University of Oxford. PQShield provides a suite of products, including PQSoC, a post-quantum system on chip co-processor toolkit; PQSDK, which integrates post-quantum primitives with the OpenSSL API; and PQE2E, a software development toolkit designed for secure data messaging in transit. These offerings facilitate the transition from traditional cryptographic methods, such as RSA and Elliptic Curve cryptography, to quantum-secure standards, ensuring that businesses can protect their data and communications against future quantum threats. The company has garnered support from InnovateUK and Oxford Sciences Innovation to advance its mission.
Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.
Alethiomics is a pre-clinical biotech company focused on developing targeted therapies for blood cancers. Utilizing advanced single-cell multi-omic technology, the company aims to discover and create innovative treatments for myeloproliferative neoplasms, which originate from mutations in cancer stem cells within the bone marrow. By leveraging this cutting-edge approach, Alethiomics seeks to provide medical professionals with effective and potentially curative therapies for patients suffering from these conditions.
Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.
The company was founded in 2015 and is headquartered in Oxford, England.
Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. The company leverages artificial intelligence to create diagnostic tools that significantly improve the accuracy of echocardiography, with reported enhancements exceeding 90%. Ultromics' technology focuses on analyzing complex data from electrocardiograms, enabling healthcare providers to make informed decisions in diagnosing coronary artery disease. By providing innovative solutions for cardiologists, Ultromics aims to transform cardiovascular diagnostics and improve patient outcomes.
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the delivery of nucleic acid therapeutics, particularly antisense oligonucleotides. Established in 2018, PepGen aims to enhance the clinical efficacy of these therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative technology employs engineered peptides designed for optimized tissue penetration, cellular uptake, and nuclear delivery, enabling effective transport of oligonucleotides to various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. By leveraging its drug delivery capabilities, PepGen seeks to transform the treatment landscape for severe neuromuscular and neurological diseases.
Rey is a membership-based, on-demand mental health company on a mission to revolutionize mental health and wellness by improving access to personalized services through technology.
Orbit Discovery Ltd. is a peptide display technology company based in Oxford, United Kingdom, founded in 2015. The company specializes in identifying peptide drugs aimed at treating chronic diseases by leveraging its innovative in vitro display technology. This technology utilizes small beads to connect randomized peptide sequences with their corresponding DNA, facilitating the screening of peptides for various disease types. Orbit Discovery focuses on developing a screening platform that identifies potential peptide drug candidates for both internal drug discovery programs and collaborative research initiatives. The company’s platform offers a means to discover and optimize novel, biologically relevant peptides, capitalizing on the unique properties of peptides that combine the specificity and efficacy of larger biologic molecules with the advantages of smaller molecules, such as reduced dosing and simpler manufacturing processes. This approach aims to enhance the discovery and development of peptide-based therapeutics.
Omega Crop is a crop model that integrates geo-statistics with a data ecosystem to anticipate crop performance risk, guide decision-making, and provide openings for growers to keep feeding the world. They use geostatistics with a data ecosystem to forecast and immediately address growers' crop performance issues.
Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel. This diverts the blood away from the aneurysm, allowing it to heal.
Caristo Diagnostics Limited, based in Oxford, United Kingdom, specializes in artificial intelligence-driven software for cardiovascular diagnostics. Founded in 2018, the company focuses on improving heart health assessments through its advanced imaging technology. By developing tools that analyze Cardiac Computed Tomography Angiography (CCTA), Caristo enables the measurement of Fat Attenuation Index (FAI) during routine heart check-ups. This innovative approach enhances the diagnostic accuracy of coronary angiograms, allowing healthcare professionals to identify inflammation in the coronary arteries and predict risks of heart attacks, strokes, and diabetes. Through its proprietary technology, Caristo Diagnostics aims to support medical professionals in making informed treatment decisions to better manage cardiovascular health.
Vaccitech Limited is a biotechnology company based in Oxford, United Kingdom, that focuses on researching and developing T cell immunotherapeutic products and vaccines. Established in 2016 as a spin-out from the University of Oxford’s Jenner Institute, the company specializes in viral vector vaccines designed to address significant health challenges, including hepatitis B, human papillomavirus, and prostate cancer. Vaccitech utilizes advanced chimpanzee adenovirus technology to elicit robust T-cell responses, fostering lasting cell-mediated immunity. The company has progressed its assets into clinical trials, showing promising initial results. Upcoming studies include a phase IIB efficacy trial for a universal influenza vaccine targeting individuals aged 65 and older, as well as an extended phase I trial for prostate cancer treatment, reflecting Vaccitech's commitment to advancing innovative therapeutic solutions.
Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing exosome-based therapeutics for the treatment of severe diseases. Founded in 2016, the company leverages its proprietary technology to harness and engineer extracellular vesicles, known as exosomes, for the targeted delivery of nucleic acids and proteins. This innovative approach aims to enhance drug delivery to challenging areas, such as the brain and central nervous system, where conventional therapies often fall short. Evox’s mission is to improve human health by creating novel therapeutics that address significant medical needs, particularly for conditions with limited treatment options. The company has built a comprehensive intellectual property portfolio and is backed by prominent life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based drug delivery.
SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines through its proprietary biotechnology platform. The company utilizes a unique molecular superglue to bond antigens to viruses and other particles, facilitating the rapid creation of vaccines aimed at a variety of diseases. This advanced technology enables medical institutions and research centers to produce next-generation vaccines that demonstrate improved efficacy and reduced development time, thereby enhancing the overall vaccine development process.
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies. The company was formed in 2017 to drive the development of a pipeline of novel clinical trial candidates, and is led by a team that combines over 40 years of experience in oncolytic virus development. The company uses an adenovirus platform to develop targeted, self-amplifying therapeutic agents, and aims to deliver innovative cancer care to millions of people in need worldwide.
Living Optics Limited is a company based in Oxford, United Kingdom, that specializes in the design and development of advanced imaging technology. Established in 2019, the company focuses on a compact hyperspectral camera system that utilizes innovative hardware design and software processing. This technology captures data beyond the capabilities of the human eye and conventional cameras, making hyperspectral imaging more accessible and affordable. Living Optics' products cater to a diverse array of applications, including consumer products, medical devices, and various industrial sectors. The company primarily serves computer vision developers and scientists, enabling them to integrate spectral imaging data into new applications and research initiatives.
DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, specializes in the design and discovery of innovative therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company is focused on addressing significant unmet medical needs through the development of new medicines, an inherently challenging process often hindered by traditional methodologies. DJS Antibodies utilizes a breakthrough technology that enhances the success rate of discovering lead antibodies, a process that has garnered early support from Johnson & Johnson. This approach has facilitated the advancement of lead programs aimed at treating cancer and kidney disease, positioning DJS Antibodies as a leader in the field of drug development.
T-Cypher Bio is an early-stage biotechnology company focused on developing T-cell receptor (TCR)-based therapeutics aimed at treating solid tumors as well as autoimmune, inflammatory, and infectious diseases. The company addresses the challenges associated with identifying therapeutically relevant targets and TCRs through its integrated platform, D-Cypher. This platform employs advanced techniques to generate target screening libraries, enabling the identification of functionally defined T-cell clones directly from disease tissues. By offering an end-to-end approach to cell therapy development and patient treatment, T-Cypher Bio aims to provide innovative solutions that could significantly enhance cancer care and address various health conditions.
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the delivery of nucleic acid therapeutics, particularly antisense oligonucleotides. Established in 2018, PepGen aims to enhance the clinical efficacy of these therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative technology employs engineered peptides designed for optimized tissue penetration, cellular uptake, and nuclear delivery, enabling effective transport of oligonucleotides to various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. By leveraging its drug delivery capabilities, PepGen seeks to transform the treatment landscape for severe neuromuscular and neurological diseases.
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the delivery of nucleic acid therapeutics, particularly antisense oligonucleotides. Established in 2018, PepGen aims to enhance the clinical efficacy of these therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative technology employs engineered peptides designed for optimized tissue penetration, cellular uptake, and nuclear delivery, enabling effective transport of oligonucleotides to various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. By leveraging its drug delivery capabilities, PepGen seeks to transform the treatment landscape for severe neuromuscular and neurological diseases.
Refeyn specializes in label-free single molecule imaging and mass measurement, offering advanced microscopy solutions for detecting and quantifying molecules. Their technology enables users to perform precise imaging, localization, and accurate mass determination of individual biomolecules in solution. This innovative approach serves various sectors, particularly pharmaceutical, biomedical, and research industries. Founded in 2018 and headquartered in Oxford, United Kingdom, Refeyn aims to enhance research capabilities by providing tools that facilitate a deeper understanding of molecular interactions and properties.
ORCA Computing Limited, founded in 2019 and based in Oxford, United Kingdom, specializes in the development of photonic quantum computers. The company is focused on creating a scalable and flexible quantum computing platform that utilizes quantum memories to enhance performance. By integrating proprietary memory technology with standard telecom components, ORCA Computing delivers a modular architecture that optimizes the storage, synchronization, and buffering of quantum operations. This innovative approach aims to unlock advanced applications across various industries, thereby accelerating innovation and transforming traditional computing methods.
PQShield Ltd specializes in quantum-secure cryptographic solutions aimed at addressing emerging security challenges posed by quantum computing. Founded in 2018 and based in Oxford, UK, the company originated as a spinout from the Mathematical Institute at the University of Oxford. PQShield provides a suite of products, including PQSoC, a post-quantum system on chip co-processor toolkit; PQSDK, which integrates post-quantum primitives with the OpenSSL API; and PQE2E, a software development toolkit designed for secure data messaging in transit. These offerings facilitate the transition from traditional cryptographic methods, such as RSA and Elliptic Curve cryptography, to quantum-secure standards, ensuring that businesses can protect their data and communications against future quantum threats. The company has garnered support from InnovateUK and Oxford Sciences Innovation to advance its mission.
Developer of advanced quantum computing systems designed to create chips for high-performance applications. The company's platform features trapped-ion technology that enables scalability and efficiency, utilizing standard semiconductor fabrication methods to produce quantum chips globally, enabling clients to facilitate significant advancements in the quantum computing market and providing enhanced computational capabilities for complex problem-solving.
Oxford Flow Ltd. specializes in the design, manufacture, and supply of pressure control equipment, including gas regulators, water pressure reducing valves, silencers, and pilots. Established in 2015 and headquartered in Oxford, United Kingdom, the company serves a diverse range of industries such as water, gas, marine, oil and gas, process, power, and building services. Oxford Flow combines expertise from academia and industry to create practical solutions that enhance operational efficiency while minimizing environmental impact. Each of their products is developed through rigorous testing and customer feedback, ensuring reliability and performance in challenging conditions.
Base Genomics Limited is an epigenetics company focused on advancing DNA methylation technology through its innovative TAPS (TET-assisted pyridine borane sequencing) method. Developed at the Ludwig Institute for Cancer Research at the University of Oxford, TAPS allows for the simultaneous generation of genetic and epigenetic information at base resolution. This technology addresses the limitations of traditional bisulfite sequencing by preserving DNA integrity, thus providing more high-quality data from smaller samples. Base Genomics targets various significant markets, including early cancer detection, minimal residual disease analysis, patient monitoring, and non-invasive prenatal testing. The company aims to enhance medical practices by offering reliable and efficient methods for cancer detection and monitoring, ultimately transforming patient outcomes. Base Genomics was founded in 2019 and is based in Oxford, United Kingdom.
Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.
The company was founded in 2015 and is headquartered in Oxford, England.
Quantum Motion Technologies Limited is focused on developing a universal quantum computer utilizing silicon-based technology and CMOS-compatible processes. Founded in 2017 and based in Leeds, United Kingdom, the company aims to create scalable quantum computing architectures that address issues such as fault tolerance and qubit redundancy. Its technology is designed to enhance qubit density, allowing for the construction of large-scale quantum systems capable of solving complex problems in various fields, including chemistry, medicine, and artificial intelligence. By leveraging advanced architectural approaches, Quantum Motion Technologies seeks to advance the quantum technology sector and provide solutions that reduce errors and overcome critical challenges in quantum information processing.
BibliU is a digital educational service designed to enhance the learning experience for university students. It provides access to a vast library of textbooks and monographs, allowing students to search for relevant materials easily. The platform also facilitates interaction among students and professors, promoting collaborative learning and engagement. By streamlining access to educational content, BibliU aims to make the learning process more efficient and effective.
Living Optics Limited is a company based in Oxford, United Kingdom, that specializes in the design and development of advanced imaging technology. Established in 2019, the company focuses on a compact hyperspectral camera system that utilizes innovative hardware design and software processing. This technology captures data beyond the capabilities of the human eye and conventional cameras, making hyperspectral imaging more accessible and affordable. Living Optics' products cater to a diverse array of applications, including consumer products, medical devices, and various industrial sectors. The company primarily serves computer vision developers and scientists, enabling them to integrate spectral imaging data into new applications and research initiatives.
Perspectum Diagnostics Ltd. is a medical technology company based in Oxford, United Kingdom, with additional offices in Singapore and the United States. Founded in 2012, it specializes in developing innovative technologies for diagnosing and measuring liver diseases through advanced magnetic resonance imaging. The company's flagship product, LiverMultiScan, provides objective and quantitative assessments of liver health, aiding in the detection and measurement of liver, gallbladder, and pancreatic diseases, including precancerous and cancerous conditions. Perspectum's technologies are also utilized in clinical trials to evaluate investigational therapies for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. By focusing on precision medicine, Perspectum aims to enhance patient care through early detection, accurate diagnosis, and targeted treatment, leveraging a diverse team of experts in medicine and technology. As of March 2020, the company operates as a subsidiary of Ambra Health, Inc.
OMass Technologies Ltd engages in drug discovery by applying mass spectrometry to the characterization of intact protein assemblies. The company offers biotherapeutics, membrane proteins, drug binding, and purifications guiding services. In addition, OMass Technologies Ltd offers structural mass spectrometry (MS) platforms, often referred to as native mass spectrometry, for characterizing complex protein assemblies. The company assists biotechnology and pharmaceutical companies in tackling drug targets and biotherapeutics. OMass Technologies Ltd was founded in 2016 and is based in Begbroke, United Kingdom.
Oxford VR Limited, founded in 2016 and based in Oxford, United Kingdom, specializes in developing automated cognitive treatments for various clinical conditions, including fear of heights, psychosis, and social anxiety. Originating from research at Oxford University by Professor Daniel Freeman, the company harnesses immersive virtual reality technology to deliver therapy through a virtual coach. This innovative approach aims to significantly increase access to mental health treatments, making them faster, more effective, and lower in cost compared to traditional methods. Oxford VR focuses on creating clinically validated and user-centered therapies that not only benefit patients but also positively impact the healthcare system and the broader economy.
OxMet Technologies develops, licenses, and manufactures proprietary alloys, alloy powders and alloy components for the aerospace, automotive, industrial and biomedical markets.
Mixergy Ltd, founded in 2014 and based in Cassington, United Kingdom, specializes in the development of energy storage solutions, particularly hot water tanks. The company provides a cost-effective means to enhance energy efficiency and support renewable energy generation by improving grid balancing. Mixergy's innovative tanks are designed to optimize the use of solar photovoltaic systems and heat pumps, thereby enabling better energy utilization and contributing to sustainable energy practices.
MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on developing antibody modulators for immune cell receptors aimed at treating autoimmune diseases. Founded in 2018, MiroBio leverages pioneering research from the University of Oxford to understand how immune cells communicate and are activated. This foundational knowledge allows the company to create innovative antibodies that stimulate specific immune cell signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural pathways, MiroBio's therapeutics aim to provide significant benefits to patients suffering from various autoimmune conditions, enabling clinicians to effectively manage overactive immune responses associated with these diseases.
YASA Motors Ltd. specializes in the manufacture of axial flux motors and generators tailored for electric and hybrid vehicles, as well as for various industrial applications. Established in 2009, the company produces a range of electric motors, including low-speed high-torque models and those designed for higher speed and power applications. YASA's innovative motor technology is particularly suited for sectors such as automotive, aerospace, marine, and construction equipment, where it addresses needs for traction, propulsion, and power generation. In addition to standard products, YASA offers custom motor solutions and consultancy services, which encompass electrical architecture design and thermal modeling. The company operates from its headquarters in Yarnton, United Kingdom, where it focuses on developing efficient, lightweight motors that meet the increasing global demand for reduced emissions and improved energy efficiency across multiple industries.
MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that specializes in developing sustainable agricultural technologies. Founded in 2017 as a spin-out from the University of Oxford, the company focuses on discovering new herbicide chemistries with innovative modes of action derived from both natural and synthetic sources. By utilizing a proprietary in vivo plant-based genomic process, MoA Technology identifies specific target proteins linked to these new modes of action, thus providing farmers with a diverse range of effective weed control solutions. The company's approach aims to enhance food production while promoting sustainable crop systems.
Oxford Semantic Technologies develop RDFox, the first market-ready high-performance knowledge graph designed from ground up with semantic reasoning in mind. Oxford Semantic Technologies was founded in 2017 as a spin-out of the University of Oxford with a mission to bring cutting-edge research in semantic web technologies to industry. The team started working on RDFox in 2011 at the Computer Science Department of the University of Oxford with the conviction that flexible and high-performance reasoning was a possibility for data extensive applications without jeopardising the correctness of the results. Patented modern computing techniques underpin RDFox’s ability to deliver responses to complex queries on the fly. This has unlocked a new wave of enterprise applications for prestigious partners.
Albus Health is a medical device company that develops a passive and non-contact, nocturnal symptom monitoring device. The company develops Albus Home RD, a completely passive and non-contact home monitoring device that enables a high quantity and quality of data from remote monitoring in research and clinical care.
Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.
OMass Technologies Ltd engages in drug discovery by applying mass spectrometry to the characterization of intact protein assemblies. The company offers biotherapeutics, membrane proteins, drug binding, and purifications guiding services. In addition, OMass Technologies Ltd offers structural mass spectrometry (MS) platforms, often referred to as native mass spectrometry, for characterizing complex protein assemblies. The company assists biotechnology and pharmaceutical companies in tackling drug targets and biotherapeutics. OMass Technologies Ltd was founded in 2016 and is based in Begbroke, United Kingdom.
OxMet Technologies develops, licenses, and manufactures proprietary alloys, alloy powders and alloy components for the aerospace, automotive, industrial and biomedical markets.
Covatic Ltd, established in 2016 and headquartered in Birmingham, United Kingdom, specializes in broadcast personalization software. The company utilizes mobile-based algorithms to enhance user experiences through smart personalization in applications. With an additional office in London, Covatic aims to refine its technology and expand its offerings, focusing on developing innovative solutions that meet the needs of its users. The team is composed of dedicated problem solvers committed to advancing their products and fostering partnerships with like-minded individuals and organizations.
Animal Dynamics specializes in developing advanced robotics inspired by the efficiency and elegance found in nature. The company leverages recent advancements in analytical technologies to deeply analyze high-performance animals, aiming to understand the fundamental mechanisms that drive their capabilities. By merging fine engineering with insights from evolutionary biomechanics, Animal Dynamics creates innovative robotic vehicles designed for various applications, including crop spraying, surveying, fire suppression, humanitarian efforts, emergency aid, and military resupply. Their approach not only seeks to replicate natural designs but also aims to surpass existing engineering capabilities, contributing to both the advancement of technology and environmental protection.
Caristo Diagnostics Limited, based in Oxford, United Kingdom, specializes in artificial intelligence-driven software for cardiovascular diagnostics. Founded in 2018, the company focuses on improving heart health assessments through its advanced imaging technology. By developing tools that analyze Cardiac Computed Tomography Angiography (CCTA), Caristo enables the measurement of Fat Attenuation Index (FAI) during routine heart check-ups. This innovative approach enhances the diagnostic accuracy of coronary angiograms, allowing healthcare professionals to identify inflammation in the coronary arteries and predict risks of heart attacks, strokes, and diabetes. Through its proprietary technology, Caristo Diagnostics aims to support medical professionals in making informed treatment decisions to better manage cardiovascular health.
Oxford VR Limited, founded in 2016 and based in Oxford, United Kingdom, specializes in developing automated cognitive treatments for various clinical conditions, including fear of heights, psychosis, and social anxiety. Originating from research at Oxford University by Professor Daniel Freeman, the company harnesses immersive virtual reality technology to deliver therapy through a virtual coach. This innovative approach aims to significantly increase access to mental health treatments, making them faster, more effective, and lower in cost compared to traditional methods. Oxford VR focuses on creating clinically validated and user-centered therapies that not only benefit patients but also positively impact the healthcare system and the broader economy.
Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing exosome-based therapeutics for the treatment of severe diseases. Founded in 2016, the company leverages its proprietary technology to harness and engineer extracellular vesicles, known as exosomes, for the targeted delivery of nucleic acids and proteins. This innovative approach aims to enhance drug delivery to challenging areas, such as the brain and central nervous system, where conventional therapies often fall short. Evox’s mission is to improve human health by creating novel therapeutics that address significant medical needs, particularly for conditions with limited treatment options. The company has built a comprehensive intellectual property portfolio and is backed by prominent life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based drug delivery.
Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.
Edplus is an education technology company focused on enhancing the learning experience through an AI-based platform. The platform employs an adaptive-learning algorithm that personalizes questions for individual learners, making education more accessible and efficient. By utilizing machine learning, Edplus optimizes its educational strategies across various subjects, including math, science, and languages. The company's mission is to simplify the learning process, enabling school-aged children to grasp concepts more effectively and learn at their own pace.
BioBeats Group Ltd designs and develops an online platform BioBeats, that is a machine learning platform that measures biometrics and manages stress and wellness of individuals, employees, and patients in real-time, and helps them action that insight through engaging media. Its application is available for download on Android and iOS devices. The company was incorporated in 2011 and is based in London, United Kingdom.
Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.
Metaboards is a pioneer in the field of metamaterials, specializing in the development of innovative solutions for wireless charging. The company focuses on creating materials that possess unique properties not found in nature, allowing for the wireless powering of multiple electronic devices across large surfaces. Their technology enables devices to be charged without the need for precise alignment or multiple power inputs, eliminating vulnerabilities associated with traditional connectors. By exploring the potential of metamaterials, Metaboards aims to transform the functionality of wireless charging, providing flexible and efficient solutions for both businesses and individuals.
BibliU is a digital educational service designed to enhance the learning experience for university students. It provides access to a vast library of textbooks and monographs, allowing students to search for relevant materials easily. The platform also facilitates interaction among students and professors, promoting collaborative learning and engagement. By streamlining access to educational content, BibliU aims to make the learning process more efficient and effective.
Util is a developer of sustainability intelligence technology that provides investors with an objective, evidence-based view of a company's impact. By leveraging big data and machine learning, Util aggregates and analyzes quantified company data across various stakeholders, including employees, customers, and the environment. This data is transformed into a dollar-based annual value generated metric, allowing responsible investors to evaluate both financial and non-financial returns on investment. The company goes beyond traditional ESG metrics to present a comprehensive assessment of companies as complex value generators. Util's methodology covers all listed securities and is designed for investment managers seeking unique analysis that parallels conventional financial reporting. Currently, Util is collaborating with two investment manager partners that collectively manage $130 billion in assets to refine its products and methodologies, aiming to enhance the integration of sustainability in investment decision-making.
Opsydia Limited specializes in innovative laser marking technology that enables the creation of invisible structures within transparent materials. Founded in 2017 and based in Begbroke, United Kingdom, the company’s technology allows for the permanent and inimitable marking of serial numbers, images, and cryptographic data without altering the surface or compromising the integrity of materials like diamonds, glass, and polymers. This capability positions Opsydia to significantly enhance security and authenticity in various industries, particularly in diamond trading where identity verification is crucial. By embedding marks that are not visible to the naked eye, Opsydia's solutions provide a unique advantage in safeguarding valuable assets and improving overall material quality.
Orbit Discovery Ltd. is a peptide display technology company based in Oxford, United Kingdom, founded in 2015. The company specializes in identifying peptide drugs aimed at treating chronic diseases by leveraging its innovative in vitro display technology. This technology utilizes small beads to connect randomized peptide sequences with their corresponding DNA, facilitating the screening of peptides for various disease types. Orbit Discovery focuses on developing a screening platform that identifies potential peptide drug candidates for both internal drug discovery programs and collaborative research initiatives. The company’s platform offers a means to discover and optimize novel, biologically relevant peptides, capitalizing on the unique properties of peptides that combine the specificity and efficacy of larger biologic molecules with the advantages of smaller molecules, such as reduced dosing and simpler manufacturing processes. This approach aims to enhance the discovery and development of peptide-based therapeutics.
Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. The company leverages artificial intelligence to create diagnostic tools that significantly improve the accuracy of echocardiography, with reported enhancements exceeding 90%. Ultromics' technology focuses on analyzing complex data from electrocardiograms, enabling healthcare providers to make informed decisions in diagnosing coronary artery disease. By providing innovative solutions for cardiologists, Ultromics aims to transform cardiovascular diagnostics and improve patient outcomes.
PQShield Ltd specializes in quantum-secure cryptographic solutions aimed at addressing emerging security challenges posed by quantum computing. Founded in 2018 and based in Oxford, UK, the company originated as a spinout from the Mathematical Institute at the University of Oxford. PQShield provides a suite of products, including PQSoC, a post-quantum system on chip co-processor toolkit; PQSDK, which integrates post-quantum primitives with the OpenSSL API; and PQE2E, a software development toolkit designed for secure data messaging in transit. These offerings facilitate the transition from traditional cryptographic methods, such as RSA and Elliptic Curve cryptography, to quantum-secure standards, ensuring that businesses can protect their data and communications against future quantum threats. The company has garnered support from InnovateUK and Oxford Sciences Innovation to advance its mission.
Oxford Flow Ltd. specializes in the design, manufacture, and supply of pressure control equipment, including gas regulators, water pressure reducing valves, silencers, and pilots. Established in 2015 and headquartered in Oxford, United Kingdom, the company serves a diverse range of industries such as water, gas, marine, oil and gas, process, power, and building services. Oxford Flow combines expertise from academia and industry to create practical solutions that enhance operational efficiency while minimizing environmental impact. Each of their products is developed through rigorous testing and customer feedback, ensuring reliability and performance in challenging conditions.
6D.ai is a company that specializes in developing application programming interfaces (APIs) for the augmented reality (AR) industry. Founded in 2017 and headquartered in San Francisco, California, 6D.ai focuses on creating a real-time, three-dimensional semantic map of the world utilizing standard smartphone cameras and mobile sensors. Its platform constructs dense meshes from crowdsourced data, enabling 3D mapping and multi-user AR experiences. The technology operates in the background, capturing environmental data to facilitate the development of applications that interact meaningfully with the physical world. As of March 2020, 6D.ai operates as a subsidiary of Niantic, Inc.
Xerion Healthcare Limited is a UK-based company focused on developing and commercializing nanoparticle treatments to enhance the effectiveness of cancer therapies, specifically targeting head, neck, and pancreatic tumors. Founded in 2015, the company utilizes titanium dioxide nanoparticles, a non-toxic semiconductor material, which are injected into tumors prior to standard radiotherapy. This innovative approach amplifies the dose of free radicals produced by X-rays, thereby improving the treatment's efficacy while minimizing potential side effects. By integrating this nanomedicine technology into conventional radiotherapy, Xerion Healthcare aims to provide more effective solutions for patients with challenging cancer types.
Latent Logic was acquired by Waymo in December 2019 and was Waymo's first engineering hub outside the US. Originally known as Morpheus Labs, Latent Logic had its roots in Oxford University’s award-winning machine learning department. It develops state-of the-art deep reinforcement learning techniques which allow robots to solve complex "human” tasks by learning from demonstration. The lead market for this technology is autonomous vehicles, where it can speed up the development of autonomous control systems, or test their performance and safety via simulated test cases with realistic human behaviours.
Odqa develop next-generation heat transport technology to tackle world scale environmental and energy problems. Developing novel methods for moving heat on scales large and small to tackle the world's most pressing environmental problems.
Bodle Technologies Limited provides advanced optoelectronic solutions for displays and smart windows. It offers zero-power reflective displays that are bi-stable reflective displays with ultra-high resolution; smart windows; and security coatings that change color under mechanical, optical or electrical probing techniques that result in unbreakable security features in currencies, ID cards, and official documentation. Its reflective displays are used in wearables, near-eye, and projection based displays. Bodle Technologies Limited was incorporated in 2015 and is headquartered in Begbroke, United Kingdom.
Vaccitech Limited is a biotechnology company based in Oxford, United Kingdom, that focuses on researching and developing T cell immunotherapeutic products and vaccines. Established in 2016 as a spin-out from the University of Oxford’s Jenner Institute, the company specializes in viral vector vaccines designed to address significant health challenges, including hepatitis B, human papillomavirus, and prostate cancer. Vaccitech utilizes advanced chimpanzee adenovirus technology to elicit robust T-cell responses, fostering lasting cell-mediated immunity. The company has progressed its assets into clinical trials, showing promising initial results. Upcoming studies include a phase IIB efficacy trial for a universal influenza vaccine targeting individuals aged 65 and older, as well as an extended phase I trial for prostate cancer treatment, reflecting Vaccitech's commitment to advancing innovative therapeutic solutions.
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the delivery of nucleic acid therapeutics, particularly antisense oligonucleotides. Established in 2018, PepGen aims to enhance the clinical efficacy of these therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative technology employs engineered peptides designed for optimized tissue penetration, cellular uptake, and nuclear delivery, enabling effective transport of oligonucleotides to various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. By leveraging its drug delivery capabilities, PepGen seeks to transform the treatment landscape for severe neuromuscular and neurological diseases.
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies. The company was formed in 2017 to drive the development of a pipeline of novel clinical trial candidates, and is led by a team that combines over 40 years of experience in oncolytic virus development. The company uses an adenovirus platform to develop targeted, self-amplifying therapeutic agents, and aims to deliver innovative cancer care to millions of people in need worldwide.
Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.
The company was founded in 2015 and is headquartered in Oxford, England.
Albus Health is a medical device company that develops a passive and non-contact, nocturnal symptom monitoring device. The company develops Albus Home RD, a completely passive and non-contact home monitoring device that enables a high quantity and quality of data from remote monitoring in research and clinical care.
First Light Fusion Limited is a company focused on developing advanced implosion processes for electricity generation. Founded in July 2011 as a spin-out from the University of Oxford, the company initially operated under the name Oxyntix Ltd. until a rebranding in June 2014. The founders, Professor Yiannis Ventikos and Dr. Nicholas Hawker, have backgrounds in mechanical engineering and academia. Based in Begbroke, United Kingdom, First Light Fusion employs a team of engineers and physicists and maintains collaborations with several prestigious academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company's mission is to innovate in the field of energy generation through cutting-edge research and technology.
Quantum Motion Technologies Limited is focused on developing a universal quantum computer utilizing silicon-based technology and CMOS-compatible processes. Founded in 2017 and based in Leeds, United Kingdom, the company aims to create scalable quantum computing architectures that address issues such as fault tolerance and qubit redundancy. Its technology is designed to enhance qubit density, allowing for the construction of large-scale quantum systems capable of solving complex problems in various fields, including chemistry, medicine, and artificial intelligence. By leveraging advanced architectural approaches, Quantum Motion Technologies seeks to advance the quantum technology sector and provide solutions that reduce errors and overcome critical challenges in quantum information processing.
Oxford Quantum Circuits developing technology using the power of quantum to do things which have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies.
Mind Foundry Limited, founded in 2015 and based in Oxford, United Kingdom, specializes in developing software that empowers organizations to extract valuable insights from their data. Established by Professors Stephen Roberts and Michael Osborne, the company leverages advanced machine learning and algorithmic modeling techniques to address complex challenges across various sectors. Mind Foundry's platform is designed to be both powerful and user-friendly, making machine learning accessible to individuals within organizations, not just data scientists. This approach enables teams to utilize data effectively, enhancing decision-making and driving business success. By fostering collaboration between AI and humans, Mind Foundry aims to help organizations unlock the potential of their data to tackle significant global issues.
Inkpath Limited is a software company that specializes in a skill tracker platform aimed at enhancing the personal and professional development of university students and administrators. Established in 2015 and based in Thame, United Kingdom, the platform facilitates users in monitoring their development, setting goals, managing courses, and tracking attendance and feedback. It features a user-friendly smartphone application that directs students to relevant training opportunities, enabling them to track their progress and export their achievements for CVs. Additionally, the platform provides valuable data-driven feedback to help students improve their employability upon graduation. By offering a comprehensive view of student development and performance, Inkpath serves as a complete solution for modern universities.
OxMet Technologies develops, licenses, and manufactures proprietary alloys, alloy powders and alloy components for the aerospace, automotive, industrial and biomedical markets.
Diffblue is changing the way software is developed using Artificial Intelligence (AI).
Diffblue Cover, the company’s first product, automatically generates tests for Java code to enable development teams to deliver higher quality software, faster. Diffblue’s technology is developed by its team of leading experts in AI, software verification and synthesis, and customers include Goldman Sachs and Amazon Web Services.
Diffblue is backed by Oxford University, Oxford Sciences Innovation and Goldman Sachs and is headquartered in Oxford, UK.
Scenic Biotech B.V., founded in 2017 and based in Amsterdam, specializes in developing genomics and immunotherapy technologies aimed at addressing cancer and rare genetic diseases at their genetic roots. The company focuses on identifying disease-suppressing genes that serve as "off-switches" for GPCR signaling, enabling innovative therapeutic interventions. Scenic Biotech's approach involves unlocking genetic modifiers that can suppress or block the effects of disease-causing mutated genes. This technology allows for the rapid identification and validation of novel drug targets, facilitating the development of disease-modifying therapeutics that aim to improve the lives of patients suffering from severe conditions.
Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. The company leverages artificial intelligence to create diagnostic tools that significantly improve the accuracy of echocardiography, with reported enhancements exceeding 90%. Ultromics' technology focuses on analyzing complex data from electrocardiograms, enabling healthcare providers to make informed decisions in diagnosing coronary artery disease. By providing innovative solutions for cardiologists, Ultromics aims to transform cardiovascular diagnostics and improve patient outcomes.
Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.
SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines through its proprietary biotechnology platform. The company utilizes a unique molecular superglue to bond antigens to viruses and other particles, facilitating the rapid creation of vaccines aimed at a variety of diseases. This advanced technology enables medical institutions and research centers to produce next-generation vaccines that demonstrate improved efficacy and reduced development time, thereby enhancing the overall vaccine development process.
Bodle Technologies Limited provides advanced optoelectronic solutions for displays and smart windows. It offers zero-power reflective displays that are bi-stable reflective displays with ultra-high resolution; smart windows; and security coatings that change color under mechanical, optical or electrical probing techniques that result in unbreakable security features in currencies, ID cards, and official documentation. Its reflective displays are used in wearables, near-eye, and projection based displays. Bodle Technologies Limited was incorporated in 2015 and is headquartered in Begbroke, United Kingdom.
Oxford Semantic Technologies develop RDFox, the first market-ready high-performance knowledge graph designed from ground up with semantic reasoning in mind. Oxford Semantic Technologies was founded in 2017 as a spin-out of the University of Oxford with a mission to bring cutting-edge research in semantic web technologies to industry. The team started working on RDFox in 2011 at the Computer Science Department of the University of Oxford with the conviction that flexible and high-performance reasoning was a possibility for data extensive applications without jeopardising the correctness of the results. Patented modern computing techniques underpin RDFox’s ability to deliver responses to complex queries on the fly. This has unlocked a new wave of enterprise applications for prestigious partners.
Pro-Mapp exists to enhance patient care and satisfy the need for ongoing evaluation and research into clinical outcomes through the use and intelligent application of patient reported outcome measures. Pro-Mapp is the culmination of years of research into and technology led implementation of patient reported outcome measures in clinical settings, we are a spin out company from Oxford University, the birth place of modern day clinical outcome measurement. We are clinically led, academically informed and technology driven.
BibliU is a digital educational service designed to enhance the learning experience for university students. It provides access to a vast library of textbooks and monographs, allowing students to search for relevant materials easily. The platform also facilitates interaction among students and professors, promoting collaborative learning and engagement. By streamlining access to educational content, BibliU aims to make the learning process more efficient and effective.